炭疽免疫研究。十、用于人体免疫的凝胶吸附保护性抗原。
Studies on immunity in anthrax. X. Gel-adsorbed protective antigen for immunization of man.
作者信息
PUZISS M, WRIGHT G G
出版信息
J Bacteriol. 1963 Jan;85(1):230-6. doi: 10.1128/jb.85.1.230-236.1963.
Abstract
Puziss, Milton (Fort Detrick, Frederick, Md.) and George G. Wright. Studies on immunity in anthrax. X. Gel-adsorbed protective antigen for immunization of man. J. Bacteriol. 85:230-236. 1963.-Protective antigen in filtrates of anaerobic cultures of Bacillus anthracis was not readily precipitable by alum or other aluminum salts, but was adsorbed onto a preformed aluminum hydroxide gel under specific conditions. The adsorbed product was highly effective in immunizing rabbits, guinea pigs, and mice against challenge with virulent B. anthracis spores. Gel-adsorbed anaerobic antigens preserved with 1:10,000 thimerosal were unstable on storage at 4 C; replacement of this preservative with 1:40,000 benzethonium chloride produced a more stable product. Addition of 0.0009% formalin further increased the stability during accelerated aging at 37 C. The final product had high protective activity in animals and was well tolerated in man.
摘要
普齐斯，米尔顿（马里兰州弗雷德里克市迪特里克堡）与乔治·G·赖特。炭疽免疫研究。十、用于人体免疫的凝胶吸附保护性抗原。《细菌学杂志》85:230 - 236。1963年。——炭疽芽孢杆菌厌氧培养滤液中的保护性抗原不易被明矾或其他铝盐沉淀，但在特定条件下可吸附到预先形成的氢氧化铝凝胶上。吸附产物在免疫兔、豚鼠和小鼠以抵抗强毒炭疽芽孢杆菌孢子攻击方面非常有效。用1:10000硫柳汞保存的凝胶吸附厌氧抗原在4℃储存时不稳定；用1:40000苄索氯铵替代这种防腐剂可产生更稳定的产物。添加0.0009%的福尔马林进一步提高了在37℃加速老化期间的稳定性。最终产物在动物中具有高保护活性，且在人体中耐受性良好。
相似文献
1
Studies on immunity in anthrax. X. Gel-adsorbed protective antigen for immunization of man.
J Bacteriol. 1963 Jan;85(1):230-6. doi: 10.1128/jb.85.1.230-236.1963.
2
Studies on immunity in anthrax. IX. Effect of variations in cultural conditions on elaboration of protective antigen by strains of Bacillus anthracis.
J Bacteriol. 1962 Mar;83(3):515-22. doi: 10.1128/jb.83.3.515-522.1962.
3
Large-scale production of protective antigen of Bacillus anthracis in anaerobic cultures.
Appl Microbiol. 1963 Jul;11(4):330-4. doi: 10.1128/am.11.4.330-334.1963.
4
Studies on immunity in anthrax. XI. Control of cellular permeability by bicarbonate ion in relation to protective antigen elaboration.
J Bacteriol. 1963 Jan;85(1):237-43. doi: 10.1128/jb.85.1.237-243.1963.
5
Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge.
Infect Immun. 2007 Aug;75(8):4020-9. doi: 10.1128/IAI.00070-07. Epub 2007 May 14.
6
Immunization against anthrax with aromatic compound-dependent (Aro-) mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen.
Infect Immun. 1990 Feb;58(2):303-8. doi: 10.1128/iai.58.2.303-308.1990.
7
Poly-gamma-d-glutamic acid and protective antigen conjugate vaccines induce functional antibodies against the protective antigen and capsule of Bacillus anthracis in guinea-pigs and rabbits.
FEMS Immunol Med Microbiol. 2009 Nov;57(2):165-72. doi: 10.1111/j.1574-695X.2009.00595.x. Epub 2009 Aug 6.
8
Immunization with a Recombinant, Pseudomonas fluorescens-Expressed, Mutant Form of Bacillus anthracis-Derived Protective Antigen Protects Rabbits from Anthrax Infection.
PLoS One. 2015 Jul 24;10(7):e0130952. doi: 10.1371/journal.pone.0130952. eCollection 2015.
9
Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants.
Infect Immun. 1992 Feb;60(2):662-8. doi: 10.1128/iai.60.2.662-668.1992.
10
Chimeric hepatitis B virus core particles carrying an epitope of anthrax protective antigen induce protective immunity against Bacillus anthracis.
Vaccine. 2008 Oct 29;26(46):5814-21. doi: 10.1016/j.vaccine.2008.08.031. Epub 2008 Sep 9.
引用本文的文献
1
A Historical Review of Military Medical Strategies for Fighting Infectious Diseases: From Battlefields to Global Health.
Biomedicines. 2022 Aug 22;10(8):2050. doi: 10.3390/biomedicines10082050.
2
Intramuscular delivery of adenovirus serotype 5 vector expressing humanized protective antigen induces rapid protection against anthrax that may bypass intranasally originated preexisting adenovirus immunity.
Clin Vaccine Immunol. 2014 Feb;21(2):156-64. doi: 10.1128/CVI.00560-13. Epub 2013 Dec 4.
3
Stochastic humoral immunity to Bacillus anthracis protective antigen: identification of anti-peptide IgG correlating with seroconversion to Lethal Toxin neutralization.
Vaccine. 2013 Apr 3;31(14):1856-63. doi: 10.1016/j.vaccine.2013.01.040. Epub 2013 Feb 13.
4
A Bacillus anthracis strain deleted for six proteases serves as an effective host for production of recombinant proteins.
Protein Expr Purif. 2011 Nov;80(1):80-90. doi: 10.1016/j.pep.2011.05.016. Epub 2011 Aug 7.
5
Integrating experimental (in vitro and in vivo) neurotoxicity studies of low-dose thimerosal relevant to vaccines.
Neurochem Res. 2011 Jun;36(6):927-38. doi: 10.1007/s11064-011-0427-0. Epub 2011 Feb 25.
6
Genetic vaccines for anthrax based on recombinant adeno-associated virus vectors.
Mol Ther. 2009 Feb;17(2):373-9. doi: 10.1038/mt.2008.242. Epub 2008 Nov 11.
7
Genetic medicine strategies to protect against bioterrorism.
Trans Am Clin Climatol Assoc. 2006;117:297-310; discussion 310-1.
8
Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity.
Infect Immun. 2005 Oct;73(10):6885-91. doi: 10.1128/IAI.73.10.6885-6891.2005.
9
Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax.
Infect Immun. 2005 Sep;73(9):5978-87. doi: 10.1128/IAI.73.9.5978-5987.2005.
10
Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed.
J Immune Based Ther Vaccines. 2004 May 12;2(1):5. doi: 10.1186/1476-8518-2-5.
本文引用的文献
1
Field Evaluation of a Human Anthrax Vaccine.
Am J Public Health Nations Health. 1962 Apr;52(4):632-45. doi: 10.2105/ajph.52.4.632.
2
The serological relationship between purified preparations of factors I and II of the anthrax toxin produced in vivo and in vitro.
J Gen Microbiol. 1960 Feb;22:219-28. doi: 10.1099/00221287-22-1-219.
3
Studies on immunity in anthrax. IX. Effect of variations in cultural conditions on elaboration of protective antigen by strains of Bacillus anthracis.
J Bacteriol. 1962 Mar;83(3):515-22. doi: 10.1128/jb.83.3.515-522.1962.
4
Purification of factor I and recognition of a third factor of the anthrax toxin.
J Gen Microbiol. 1961 Sep;26:49-63. doi: 10.1099/00221287-26-1-49.
5
Rapid lethal effect in rats of a third component found upon fractionating the toxin of Bacillus anthracis.
J Bacteriol. 1962 Jun;83(6):1274-80. doi: 10.1128/jb.83.6.1274-1280.1962.
6
7
Production of toxin in vitro by Bacillus anthracis and its spearation into two components.
J Bacteriol. 1960 Mar;79(3):450-5. doi: 10.1128/jb.79.3.450-455.1960.
8
Studies on immunity in anthrax. VII. Carbohydrate metabolism of Bacillus anthracis in relation to elaboration of protective antigen.
J Bacteriol. 1959 Jul;78(1):137-45. doi: 10.1128/jb.78.1.137-145.1959.
9
Further purification studies on the protective antigen of Bacillus anthracis produced in vitro.
J Bacteriol. 1958 Aug;76(2):192-202. doi: 10.1128/jb.76.2.192-202.1958.
10
An agar-diffusion method for titrating Bacillus anthracis immunizing antigen and its application to a study of antigen production.
J Gen Microbiol. 1957 Oct;17(2):505-16. doi: 10.1099/00221287-17-2-505.
Zotero 插件